SI-Bone (NASDAQ:SIBN) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.
Valuation and Earnings
This table compares SI-Bone and Vapotherm’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SI-Bone||$55.38 million||9.85||-$17.45 million||($0.71)||-30.72|
|Vapotherm||$42.38 million||5.97||-$42.47 million||($13.83)||-0.87|
SI-Bone has higher revenue and earnings than Vapotherm. SI-Bone is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and price targets for SI-Bone and Vapotherm, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-Bone currently has a consensus target price of $27.00, suggesting a potential upside of 23.80%. Vapotherm has a consensus target price of $27.00, suggesting a potential upside of 125.00%. Given Vapotherm’s higher possible upside, analysts clearly believe Vapotherm is more favorable than SI-Bone.
Volatility & Risk
SI-Bone has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500. Comparatively, Vapotherm has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
This table compares SI-Bone and Vapotherm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
51.0% of SI-Bone shares are owned by institutional investors. Comparatively, 55.3% of Vapotherm shares are owned by institutional investors. 38.8% of SI-Bone shares are owned by company insiders. Comparatively, 34.4% of Vapotherm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
SI-Bone beats Vapotherm on 9 of the 13 factors compared between the two stocks.
SI-Bone Company Profile
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Vapotherm Company Profile
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.